NEW WEBINAR May 22 | Biomarker Legislation Decoded for Health Plans | Sign Up »           NEW WEBINAR May 22 | Biomarker Legislation Decoded for Health Plans | Sign Up »          NEW WEBINAR May 22 | Biomarker Legislation Decoded for Health Plans | Sign Up »
News / Healthcare News: InformedDNA Acquires gWell Health; Appoints gWell Founder Surya Singh, MD as CEO

Healthcare News: InformedDNA Acquires gWell Health; Appoints gWell Founder Surya Singh, MD as CEO

Milestone is evidence of the company’s continued evolution to accelerate and increase accessibility to precision medicine

St. Petersburg, FL – August 1, 2023 – InformedDNA®, the nation’s leading applied genomics solutions company, announced today its acquisition of gWell Health, a digital health, genomics, and wellness company. InformedDNA’s deep genomic expertise partnered with gWell’s robust technology platform will accelerate the industry’s access to tech-enabled, genomic-guided decision-making to enhance patient care. As part of the acquisition, gWell’s founder and CEO Surya Singh, MD, has transitioned to the role of InformedDNA Chief Executive Officer.

“Genomic data is the key to unlocking actionable precision medicine; however, many health plans, providers and patients still face obstacles accessing and understanding this valuable information,” said David Nixon, executive chairman of InformedDNA. “InformedDNA and gWell share the value of breaking down these barriers. By bringing gWell’s technology platform to InformedDNA’s customers, we are accelerating our efforts to infuse genomics into every healthcare decision. And with Dr. Singh at the helm, we will be able to leverage his wisdom, proven leadership, and experience building a technology platform to successfully guide the continued evolution of InformedDNA.”

The gWell platform is designed to create a personalized wellness plan for users based on DNA analysis, health history, and lifestyle. Through the addition of gWell, InformedDNA bolsters its genomic offerings to meet the critical need for attainable genomics resources, offering powerful technology and tools backed by decades of genetics expertise. InformedDNA’s existing clinical genetics experts will tap into and expand the existing gWell platform of proactive health management and patient experience tools–currently designed for musculoskeletal health–to address needs in oncology, drug metabolism, and maternity care. gWell’s solutions further strengthen InformedDNA’s ability to provide ongoing, dynamic genomic education and interaction across the care continuum.

“As a medical professional, I know firsthand that access to genomic information plays an increasingly important role in both prevention strategies and treatment optimization,” said Surya Singh, MD, InformedDNA’s new CEO. “I look forward to advancing the future of precision medicine by applying gWell’s technology-enabled approach to deliver InformedDNA’s clinical expertise, supporting increased adoption of genomics-based healthcare. Together we can make available the tools and recommendations needed for individuals to live healthier lives and ensure value-based care models can work for all stakeholders.”

Dr. Singh brings more than 20 years of healthcare leadership experience to InformedDNA, spanning a diverse array of organizations. In addition to co-founding gWell and serving as its CEO, he previously served as corporate vice president and chief medical officer at CVS Health Specialty, chief medical officer of Emerging Therapy Solutions, chief medical officer and head of product at Proventys (acquired by McKesson Corporation) and as a healthcare strategy consultant at Mckinsey & Company. Dr. Singh is also currently a senior advisor to the nonprofit Institute for Clinical and Economic Review (ICER). He is board certified in internal medicine; previously practicing as an attending physician at the Brigham & Women’s Hospital, and has taught periodically at Harvard Medical School over more than 15 years.

InformedDNA was advised by the Bass Berry and Trifecta law firms. gWell Health was advised by the Nutter McClennan & Fish law firm. Financial terms of the transaction were not disclosed.

About InformedDNA

With the highest quality, most current genomics insights delivered on a technology platform built specifically for genomics-informed care management, InformedDNA delivers value-based solutions that guide and optimize genomics-related decisions affecting clinical policy, payment policy, test management, clinical research, and patient and provider experiences. We have managed genomic health benefits for more than 135 million covered lives and have navigated hundreds of thousands of people to the right genomics-based treatments or clinical trials. For more information, visit www.InformedDNA.com.

About gWell Health

Founded by physicians, gWell emerged to fill the void of inequitable access to technology-enabled precision healthcare for the average individual. gWell’s mission is to empower people of every socioeconomic and health status to take charge of their personal well-being by transforming access to precision healthcare, and to utilize genomics in reshaping and improving wellness. gWell’s initial clinical focus is on musculoskeletal health & wellness and it is closely advised by a diverse group of experienced leaders from academia, managed care, and healthcare technology. For more information, visit www.gwellhealth.com.

Recent Posts

The Cancer Letter: Joint byline, ‘Is gastrectomy indicated?’

A study recently published in JAMA sheds light on cancer risks associated with carrying germline CDH1 mutations, challenging previous, potentially inflated, lifetime cancer risk estimates. InformedDNA, FORCE: Facing Our Risk of Cancer Empowered, and No Stomach For Cancer, collaborate as patient advocates, educators, and experts to support individuals and families impacted by gastric cancer to help them navigate this complex genetic landscape. Subscribers to The Cancer Letter can login to read the full article.

Read More »

How can we help?

Reach out today to discover how our dynamic solutions can help your organization make informed decisions, manage utilization of genetic tests, and control costs for cost-effective enhanced patient care and better outcomes for all.

×